JAK2 inhibitors in the treatment of myeloproliferative neoplasms

Related Experiment Video

Updated: May 18, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Raoul Tibes1, James M Bogenberger, Holly L Geyer

  • 1Mayo Clinic, Hematology, 200 First Street SW, Rochester, MN 55905, USA. Tibes.raoul@mayo.edu

Expert Opinion on Investigational Drugs
|September 21, 2012
PubMed
Abstract

Insights

Dysregulation of Janus kinase-Signal transducer and activator of transcription (JAK-STAT) signaling drives myeloproliferative neoplasms (MPNs). JAK inhibitors show activity, and targeting parallel pathways may offer new therapeutic strategies for MPNs.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Dysregulated JAK-STAT signaling is central to myeloproliferative neoplasms (MPNs) pathogenesis.
  • Molecular aberrations include mutations in JAK2, MPL, SH2B3, and epigenetic factors like SOCS proteins.
  • Growth factor/cytokine signaling also activates JAK-STAT pathways in MPNs.

Purpose of the Study:

  • To review molecular events activating JAK-STAT signaling in MPNs.
  • To present kinase profiles of JAK inhibitors and summarize clinical trial data.
  • To discuss limitations and potential combination therapies for JAK-STAT targeting in MPNs.

Main Methods:

  • Review of mutations and molecular events in MPN pathogenesis.
  • Presentation of inhibitory kinase profiles for JAK inhibitors.
  • Comprehensive summary of clinical trial results for JAK-targeting agents.

Main Results:

  • JAK2 inhibitors are effective in MPNs with JAK2V617F and wild-type JAK2.
  • JAK2V617F mutation-specific or JAK2-selective inhibitors may offer distinct clinical benefits.
  • Targeting parallel pathways alongside JAK inhibition presents novel therapeutic avenues.

Conclusions:

  • Aberrant JAK-STAT signaling is a key driver in MPN pathogenesis.
  • Understanding JAK-STAT pathway activation is crucial for identifying therapeutic vulnerabilities.
  • Combination therapies targeting parallel pathways alongside JAK inhibition hold promise for MPN treatment.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...